Anlon Healthcare Limited has announced its standalone unaudited financial results for the quarter and nine months ended December 31, 2025, demonstrating a powerful financial turnaround. The company reported a significant surge in revenue from operations to ₹35.58 Crores, representing a 280.1% increase compared to ₹9.36 Crores in the corresponding quarter of the previous year. Net profit for the quarter stood at ₹5.15 Crores, a remarkable recovery from a net loss of ₹2.49 Crores in the same period last year. On a quarter-on-quarter basis, revenue grew from ₹52.23 Crores in Q2 FY26 to ₹35.58 Crores, while net profit transitioned from ₹9.32 Crores to ₹5.15 Crores. The board also approved the appointment of Mr. Naimish Dilipbhai Bhatt as the new Chief Financial Officer following the resignation of Mr. Hitesh Bavanjibhai Makwana.

Incorporated in 2013, Anlon Healthcare Limited is a research-intensive chemical manufacturing company based in Rajkot, Gujarat. The company specializes in producing high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for a wide range of applications, including human health, nutraceuticals, personal care, and veterinary products. Anlon operates a WHO-GMP and ISO-certified facility and has established a global footprint, exporting its products to over 15 countries, including Germany, Italy, and Japan. The company distinguishes itself through custom synthesis capabilities for complex chemical compounds and maintains a strong focus on research and development with multiple dedicated labs.